Glucotrack, Inc. (GCTK): Entry into a Material Definitive Agreement
Glucotrack, Inc. (GCTK) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Glucotrack, Inc. Announces Reverse Stock Split 1-for-2 reverse stock split to become effective as of the opening of trading on October 26, 2026 RUTHERFORD, N.J., and LA JOLLA, C.A., October 22, 2026 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
How this was made
The 30-second read
Why it matters
The split is a corporate action aimed at meeting Nasdaq listing standards; it does not change ownership percentages but may affect liquidity and price perception.
Market read
The reverse split is a compliance‑driven corporate action that could modestly affect the stock's price and attract institutional interest.
What to watch
Potential dilution from future equity raises and the company's underlying cash burn are not addressed by the split.
Background
Glucotrack is a Nasdaq‑listed healthcare technology and biopharma company that previously completed a 1‑for‑15 split in Aug 2026.
Ticker impact
Glucotrack filed an 8‑K announcing a 1‑for‑2 reverse stock split effective at the open of trading on Oct 26, 2026 to regain Nasdaq $1.00 minimum price compliance.
potential upward pressure as the split lifts price toward the $1.00 threshold
Reverse splits are typically priced in by the market; the primary driver is compliance with Nasdaq listing rules, not fundamental change.
Market effects
May improve perception of micro‑cap biotech/health‑tech sector compliance risk.
Limited to US Nasdaq micro‑cap segment.
Minimal global impact beyond the issuer.
Counterpoint
If the split fails to sustain price above $1.00, the stock could face delisting risk and further decline.
Key entities
- companyGlucotrack, Inc.
Nasdaq‑listed biotech/health‑tech firm executing the reverse split.
- regulatory_bodyNasdaq Hearings Panel
Granted an exception requiring a $1.00 minimum bid price until Nov 9, 2026.
